Opinion statement
Patients with chronic intestinal pseudoobstruction (CIP) experience a constellation of symptoms including abdominal pain, nausea, fullness, and malaise which fluctuates in severity and invariably result in a diminished quality of life. Though surgical resection or transplantation may be an option for some, there currently is no cure for CIP. Thus, management strategies utilize pharmacologic, intravenous, endoscopic, and surgical techniques to promote transit, minimize painful bloating, reduce complications of stasis, and improve quality of life. Prokinetic agents such as erythromycin, metoclopramide, cisapride, neostigmine, and tegaserod may be effective for acute exacerbations. Octreotide may reduce symptoms of bacterial overgrowth and bloating by stimulating migrating motor complexes. Enteral tubes for venting and nutritional support may reduce hospitalizations. Total parenteral nutrition (TPN), fraught with well-known complications, may be the only tolerated source for nutrients and fluid. Advanced disease may magnify nutritional problems, difficulties of long term intravenous and intestinal access, and poor symptom control. Because the initial process may manifest in other intestinal regions following surgery, resection of involved segments should be performed with caution. Small intestinal transplantation is a high-risk surgery performed in persons unable to tolerate intravenous (IV) nutrition. Optimal management for persons with CIP should not only provide nutritional and symptom focused care but should be part of a supportive network which links patients to their appropriate healthcare needs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
He CL, Burgart L, Wang L, et al.: Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology 2000, 118: 14–21.
Pardi DS, Miller SM, Miller DL, et al.: Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol 2002, 97: 1828–1833.
Sodhi N, Camilleri M, Camoriano JK, et al.: Autonomic function and motility in intestinal pseudoobstruction caused by paraneoplastic syndrome. Dig Dis Sci 1989, 34: 1937–1942.
Darnell RB, DeAngelis LM: Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993, 341: 21–22.
Kuemmerle J, Foxx-Orenstein A: Narcotic bowel syndrome. Reg Peptide Letter 1994, 5: 68–69.
Schuffler MD: Chronic intestinal pseudo-obstruction syndromes. Med Clin North Am 1981, 65: 1331–1358.
Faulk DL, Anuras S, Freeman JB: Idiopathic chronic intestinal pseudo-obstruction: use of central venous nutrition. JAMA 1978, 240: 2075–2076.
Mousa H, Hyman PE, Cocjin J, et al.: Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002, 47: 2298–2305.
Vassallo MJ, Camilleri M, Sullivan SN, Thomforde GM: Effects of erythromycin on gut transit in pseudoobstruction due to hereditary coproporphyria [Comment]. J Clin Gastroenterol 1992, 14: 255–259.
Minami T, Nishibayashi H, Shinomura Y, Matsuzawa Y: Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996, 31: 855–859.
Lipton AB, Knauer CM: Pseudo-obstruction of the bowel: therapeutic trial of metoclopramide. Am J Dig Dis 1977, 22: 263–265.
Soudah HC, Hasler WL, Owyang C: Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991, 325: 1461–1467.
Hyman PE, McDiarmid SV, Napolitano J, et al.: Antroduodenal motility in children with chronic intestinal pseudo-obstruction. J Pediatr 1988, 112: 899–905.
Di Lorenzo C, Reddy SN, Villanueva-Meyer J, et al.: Cisapride in children with chronic intestinal pseudoobstruction: an acute, double-blind, crossover, placebocontrolled trial. Gastroenterology 1991, 101: 1564–1570.
Hyman PE, Di Lorenzo C, McAdams L, et al.: Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastroenterol 1993, 88: 832–836. Report of the clinical factors in chronic intestinal pseudoobstruction that predict responsiveness to pharmacologic therapy.
Camilleri M, Balm RK, Zinsmeister AR: Symptomatic improvement with 1-year cisapride treatment in neuropathic chronic intestinal dysmotility. Aliment Pharmacol Ther 1996, 10: 403–409.
Muller-Lissner S, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation. Aliment Pharmacol Ther 2001, 15: 1655–1666.
Novick J, Miner P, Krause R, et al.: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002, 16: 1877–1688.
Degen L, Matzinger D, Merz M, et al.: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001, 15: 1745–1751.
Prather C, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000, 118: 463–468.
Mughal MM, Irving MH: Treatment of end-stage chronic intestinal pseudo-obstruction by subtotal enterectomy and home parenteral nutrition. Gut 1988, 29: 1613–1617.
Murr MM, Sarr MG, Camilleri M: The surgeon’s role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol 1995, 90: 2147–2151. Excellent discussion of experience in surgical management of chronic intestinal pseudo-obstruction.
Nayci A, Nayci A, Avlan D, Polat A, Aksoyek S: Treatment of intestinal pseudo-obstruction by segmental resection. Pediatr Surg Int 2003, 19: 44–46.
Pitt HA, Mann LL, Berquist WE, et al.: Chronic intestinal pseudo-obstruction: management with total parenteral nutrition and a venting enterostomy. Arch Surg 1985, 120: 614–618.
Grant D: Current results of intestinal transplantation: the International Intestinal Transplant Registry. Lancet 1996, 347: 1801–1803. Review of the results of intestinal transplantation for chronic intestinal pseudo-obstruction and other disorders.
Foxx-Orenstein AE, Jin JG, Grider JR: 5-HT4 receptor agonists and d-opioid receptor antagonists act synergistically to stimulate colonic propulsion. Am J Physiol 1998, 275: G979-G983. First study to identify that the combination of a 5-HT4 agonist and an opioid antagonist result in a marked increase in colonic propulsion in in vitro studies. It also discusses clinical implications.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lyford, G., Foxx-Orenstein, A. Chronic intestinal pseudoobstruction. Curr Treat Options Gastro 7, 317–325 (2004). https://doi.org/10.1007/s11938-004-0018-0
Issue Date:
DOI: https://doi.org/10.1007/s11938-004-0018-0